Senior Correspondent, London
Ben's Feed
Oct 29, 2014

Experts sound alarm as diabetes fuels cases of TB

LONDON (Reuters) – Cases of tuberculosis are set accelerate worldwide unless action is taken to curb diabetes, a chronic condition that weakens the immune system and triples the risk a person will develop the lung disease, health experts warned on Wednesday.

Tuberculosis (TB), which killed an estimated 1.5 million people last year according to the World Health Organization (WHO), is caused by bacteria that lie dormant in many people.

Oct 29, 2014

Get your facts right: Italy, U.S. come bottom in modern life survey

LONDON (Reuters) – Italians and Americans score worst when it comes to correctly assessing basic facts of modern life, such as what proportion of the population are immigrants or Muslims and what percentage of teenage girls get pregnant.

Swedes and Germans do best, although even they consistently get things wrong, according to a survey of 14 industrialized countries released on Wednesday.

Oct 28, 2014
Oct 28, 2014
Oct 27, 2014
Oct 27, 2014
Oct 27, 2014

In race for Ebola vaccines, technical hurdles loom large

LONDON (Reuters) – Drugmakers sprinting to develop Ebola vaccines face a series of technical hurdles if they are to get millions of doses ready for use next year — even assuming clinical trials are successful.

The challenges include finding sufficient sterile capacity for filling and packaging finished vials, getting fast quality approvals from regulators, and building a supply chain in Africa for products that must be stored at minus 80 degrees Celsius.

Oct 27, 2014
Oct 24, 2014

AstraZeneca cancer drug pipeline gets boost from European green light

LONDON (Reuters) – AstraZeneca’s cancer drug pipeline received a boost on Friday, as European regulators recommended approval of an experimental medicine against ovarian cancer.

The green light from the European Medicines Agency (EMA) for olaparib, or Lynparza, is welcome news since the product hit a road bump in June when a U.S. panel voted against its accelerated approval.

Oct 24, 2014
    • About Ben

      "Ben Hirschler is European pharmaceuticals, biotechnology and healthcare correspondent, based in London. Previously, he was in charge of British company news and before that was posted to Johannesburg, covering the economic challenges facing post-apartheid South Africa."
    • More from Ben

    • Follow Ben